MedTrace Logo

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

NCT01485601 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2024-02-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines compared with the standard dose of BOTOX®

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

MT10109

Single dose intramuscular injection MT10109 vs Botox®

Sponsors & Collaborators

  • Medy-Tox

    lead INDUSTRY

Principal Investigators

  • Peter Foley, Doctor · Austrailia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-07
Primary Completion
2012-03-30
Completion
2012-08-17

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01485601 on ClinicalTrials.gov